Executive Ester Baiget News Today

COPENHAGEN (Reuters) - Danish industrial enzymes maker Novozymes on Wednesday reported slightly stronger than expected first-quarter operating results...

2/2/2021 * Q4 sales, EBIT miss expectations * Firm expects 2-6% sales growth this year * CFO sees return to growth in bioethanol market in Q2 (Adds share reaction, CFO comment, analyst comment, background) By Nikolaj Skydsgaard COPENHAGEN, Feb 2 (Reuters) - Novozymes shares fell 4% on Tuesday after the enzyme maker missed fourth-quarter sales and earnings expectations, but said it expected sales to bounce back in 2021. Sales were flat in 2020, short of the 5% annual growth target set out in 201...

2/2/2021 (Adds CEO comment, details) COPENHAGEN, Feb 2 (Reuters) - Enzymes maker Novozymes on Tuesday reported fourth quarter sales and earnings slightly below expectations but said it expected sales to bounce back in 2021. In its latest strategy revamp in 2019, Novozymes said it would aim for 5% annual sales growth between 2020 and 2022. Sales growth for 2020 came in flat, however. "Despite the prevailing uncertainties, Im confident that we will get back to growth in 2021," Chief Executive Est...

By Reuters Staff 1 Min Read COPENHAGEN (Reuters) - Novozymes will acquire U.S. based Microbiome Labs in a $125 million deal, it said on Friday, its second takeover this year of a company specialising in probiotics and gut health. “Over the span of just a few years, the team at Microbiome Labs has built a solid market position and become a key opinion leader on the microbiome in the consumer health industry,” Chief Executive Ester Baiget said in a statement. The deal, financed through cash a...